Healios K.K. is a biotechnology firm specializing in the innovation, development, production, and commercialization of cell therapy and regenerative medicine products, with operations spanning Japan, Europe, and the United States. The company's robust pipeline features several advanced cellular and tissue-based therapies: iPSC-derived regenerative medicines HLCR011 and HLCR012, which target age-related macular degeneration; HLCL041, an iPSC regenerative medicine for metabolic liver disease; HLCM051, a regenerative treatment for ischemic stroke and acute respiratory distress syndrome; and HLCN061, currently under development for solid tumor indications. Furthermore, Healios K.K. maintains a collaborative research agreement with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies for mesothelioma. Founded in 2011 as Retina Institute Japan, K.K., the company rebranded to Healios K.K. in September 2013 and is headquartered in Tokyo, Japan.
The current price of 6VX.STU is €1.43 EUR — it has decreased by -4.67% in the past 24 hours. Watch Healios K.K. stock price performance more closely on the chart.
What is Healios K.K. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Healios K.K. stocks are traded under the ticker 6VX.STU.
What is Healios K.K. market cap?▼
Today Healios K.K. has the market capitalization of 193.05M
When is the next Healios K.K. earnings date?▼
Healios K.K. is going to release the next earnings report on November 18, 2026.
What were Healios K.K. earnings last quarter?▼
6VX.STU earnings for the last quarter are 0.05 EUR per share, whereas the estimation was -0.01 EUR resulting in a +517.09% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Healios K.K. have?▼
As of September 29, 2026, the company has 75 employees.